Bio Protocol Raises $6.9M Seed Round Led by Maelstrom Fund




Bio Protocol Raises $6.9M Seed Round Led by Maelstrom Fund

Key Takeaways

• Bio Protocol secured $6.9 million in seed funding led by Arthur Hayes’ Maelstrom Fund, with participation from major venture firms. 
• The DeSci platform allows scientists to create decentralised AI agents (“BioAgents”) to accelerate research and attract funding. 
• The new capital will expand Bio V2, a platform upgrade introducing Ignition Sales, staking, and the BioXP rewards programme.

Bio Protocol Secures $6.9 Million in Seed Round

Decentralised science protocol Bio has raised $6.9 million in a seed round led by Arthur Hayes’ Maelstrom Fund, with backing from Mechanism Capital, Animoca Brands, Zee Prime Capital, Panga Capital, Mirana Ventures, Foresight Ventures, Big Brain Holdings, and others.

The announcement follows the launch of Bio V2, the protocol’s upgraded platform designed to build an onchain “scientific superintelligence.”

While Bio declined to share fundraising details such as valuation or round structure, the firm confirmed that earlier backers include YZi Labs (formerly Binance Labs). William Fang, head of strategy at Bio, noted the seed funding will help scale BioAgents and extend adoption across multiple scientific domains.

Bio Protocol’s Mission: Onchain Scientific Superintelligence

At its core, Bio enables researchers to convert their scientific work into decentralised AI agents known as BioAgents. These digital agents can generate hypotheses, streamline research, and raise funding through token sales.

The model is built on the broader decentralised science (DeSci) movement, which leverages blockchain to democratise access to funding, open data, and scientific collaboration. Instead of relying on traditional institutions, research priorities are set transparently onchain, with funding allocated via DAOs.

Bio founder and CEO Paul Kohlhaas compared the platform to digital publishing. “Just as digital publishing gave creators the power to build audiences outside legacy media, Bio’s infrastructure can empower scientists to monetise research outside the traditional pharma system,” he said.

Aubrai: The First BioAgent

Bio’s first flagship BioAgent, Aubrai, was developed in partnership with VitaDAO and longevity researcher Dr. Aubrey de Grey. Since launching less than a month ago, Aubrai has minted more than 1,000 hypotheses onchain and raised $250,000 in research funding.

Aubrai’s token surged dramatically, climbing 150x from a $269,000 pre-sale valuation to nearly $40 million at its peak. Its fully diluted valuation now sits at around $35 million, according to The Block data.

The successful debut has reinforced Bio’s position as a potential launchpad for tokenised scientific research. Hayes himself described the project as “the birth of an AI-native research market” if it continues to scale.

Bio V2 and the BioXP Rewards System

The launch of Bio V2 in August introduced several new features aimed at driving ecosystem growth. These include:

• Ignition Sales: A fundraising model for low-cap, rapid launches of BioAgents and tokenised IP.
• BioXP Rewards: A points-based system allowing users to earn rewards for staking, research contributions, and engagement.
• Staking: Users can stake the BIO token and other ecosystem tokens to earn BioXP, reinforcing liquidity and long-term participation.

More BioAgents and IP tokens are expected to roll out soon, targeting dermatology, microbiome health, brain health, and men’s health.

Clinical Progress in the Bio Ecosystem

Beyond token launches, projects within Bio’s ecosystem are advancing toward real-world clinical milestones. These include:

• VITA-FAST: A longevity programme preparing for Phase 2 trials in the UAE.
• Percepta (CLAW): A patented brain health supplement entering human studies.
• Curetopia (CURES): A pilot rare-disease programme consolidating 40 conditions into a single therapeutic strategy.

Bio said that since last year, its network has already directed more than $50 million to labs worldwide, reinforcing its mission to accelerate scientific research and decentralise discovery.

More News: Forward Industries Launches $4 Billion At-The-Market Equity Offering

Looking Ahead

With the $6.9 million seed round secured, Bio plans to expand its BioAgent framework globally, building a decentralised network of AI-powered “science machines.” The goal is to compress drug discovery and development cycles from decades to months, potentially transforming the future of medicine.

At the time of writing, the BIO token trades at $0.16, with a market capitalisation of roughly $309 million. Despite short-term volatility, Bio’s growing traction among leading venture firms and researchers highlights growing confidence in decentralised science as a new frontier for innovation.

To stay updated on crypto funding news and trends, visit our fundraising area for more insights.

The post Bio Protocol Raises $6.9M Seed Round Led by Maelstrom Fund appeared first on Ventureburn.